Recent findings on fulminant type 1 diabetes

Area of Science:

• Endocrinology
• Immunology
• Diabetes Research

Background:

• Fulminant type 1 diabetes (fT1D) is a distinct subtype of type 1 diabetes characterized by rapid pancreatic beta cell destruction.
• fT1D presents with severe metabolic derangement, often more pronounced than in classic autoimmune type 1 diabetes.
• The condition's etiology may involve both innate and acquired immune system dysfunctions, including enterovirus infections.

Purpose of the Study:

• To summarize the characteristics and diagnostic criteria of fulminant type 1 diabetes.
• To highlight the immunological underpinnings and clinical presentation of fT1D.
• To discuss the association of fT1D with pregnancy and update diagnostic guidelines.

Main Methods:

• Review of existing literature on fulminant type 1 diabetes.
• Analysis of immunological factors, including HLA associations and immune responses.
• Evaluation of diagnostic markers, such as the serum glycated albumin to glycated hemoglobin ratio.

Main Results:

• fT1D is associated with specific HLA genotypes (DRB1*04:05DQB1*04:01).
• Innate and adaptive immune responses, particularly to enteroviruses, contribute to beta cell destruction.
• A serum glycated albumin to hemoglobin ratio cutoff of 3.2 demonstrates high sensitivity (97%) and specificity (98%) for differentiating fT1D from type 2 diabetes.

Conclusions:

• Fulminant type 1 diabetes is a rapidly progressing form of diabetes with unique immunological and clinical features.
• The rapid destruction of beta cells leads to severe metabolic disturbances and limited recovery of insulin secretion.
• Updated diagnostic criteria, including the glycated albumin to hemoglobin ratio, aid in differentiating fT1D, with associations noted in pregnancy.